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Abstract Human papilloma virus (HPV) is considered to
be responsible for a large part of vaginal and vulvar car-
cinomas, and the p53 codon 72 polymorphism has been
implicated in susceptibility to cancer induced by this virus,
but with contradicting results. In this study, we have
investigated the prognostic value of the codon 72 poly-
morphism by real-time PCR (qPCR) in two cohorts of
vaginal (n = 66) and vulvar (n = 123) carcinomas. In
vaginal carcinoma, arginine homozygous patients were
significantly associated with a higher primary cure rate
(p = 0.023) but also associated with a higher recurrence
rate (p = 0.073), significant at distant locations
(p = 0.009). No significant differences were found in
overall survival rate (p = 0.499) or cancer-specific sur-
vival rate (p = 0.222). A higher frequency of arginine
homozygosity was noted in HPV-positive tumors
(p = 0.190) in comparison with HPV-negative tumors. In
vulvar carcinoma, the genotype homozygous for arginine
was significantly associated with a larger tumor size at
diagnosis in the entire cohort (p = 0.015) and a lower
cancer-specific survival rate (p = 0.024) compared with
heterozygous (arginine/proline) in HPV-negative tumors.
Our results indicate that the relation between HPV and the
p53 codon 72 polymorphism is complex and the signifi-
cance and mechanisms responsible for this relationship
need to be further elucidated.
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Introduction
Both cancers of the vagina and vulva are relatively rare
cancers and account for approximately 2 and 4–5% of all
gynecological cancers, respectively [1]. Vaginal and vulvar
cancers mostly affect the elderly women, but an increasing
incidence in somewhat younger women has been reported
during the last decade [2]. Risk factors include smoking,
early sexual debut, several sexual partners during life and
human papilloma virus (HPV) infection [2]. Histologically,
squamous cell carcinoma (SCC) accounts for 80–90% of
the vaginal and 90% of the vulvar cancers with the
remaining part mainly consisting of adenocarcinoma,
melanoma and sarcoma [1]. SCC has in turn been further
morphologically characterized into basaloid, keratinizing,
non-keratinizing and verrucous carcinoma. The keratiniz-
ing form is a result of chronic vulvar dermatosis, is mostly
unrelated of HPV infection, and generally affects older
women, while the basaloid and warty forms are more
common in relatively younger women and are associated
with HPV infection [3–5].
HPV is a selective virus that infects squamous epithelia
and mucous membranes and has been associated with
anogenital cancers, such as cervical, penile, vulvar, vaginal
and anal cancer as well as head and neck cancer [6]. In
cervical carcinoma, the relation with HPV has been
extensively studied and the virus is considered to be pre-
sent in almost all cases [7]. Studies on HPV prevalence in
vaginal and vulvar cancers have been sparse and the HPV
positivity diverse, ranging between 43 and 70% in vaginal
cancer [3, 4, 8–10] and 19–40% in vulvar cancer
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[3, 5, 11, 12], but with a unanimous result of HPV-16 being
the most common genotype for both cancers. HPV-positive
vaginal and vulvar cancers largely develop through a
pathway shared with cervical cancer. The lower percentage
of HPV-related cancers in vagina and vulva compared to
cervix has been thought to depend on different morpholo-
gies and expression patterns of the cells [13] or age-related
factors such as estrogen deficiency [8]. Other reasons for
cancer development in these locals include occurrence of
chronic inflammation or lichen sclerosus.
Survival has been related to stage and size of the tumor
at diagnosis in both vaginal and vulvar carcinomas
[8–11, 14]. HPV positivity has been shown to be a favor-
able prognostic marker for overall survival for vaginal
cancer, but the same relationship has yet to be shown for
vulvar cancer [4, 5, 10, 11].
The oncogenic effect of HPV is linked to its expression
of two proteins, the E6 protein stimulating p53 degradation
and telomerase activity, and the E7 protein binding to the
retinoblastoma protein performing interactions with several
other proteins important for cell growth. E6 and E7 pro-
teins are therefore regarded as viral oncoproteins [6]. When
the expression of these oncogenes is constitutively high, it
can disturb the genomic stability leading to chromosomal
changes which in turn give rise to activation of oncogenes
or loss of tumor suppressor genes resulting in malignant
growth [15]. In an HPV-positive tumor, the viral oncogenes
are likely to promote the increased proliferation while in a
tumor lacking a virus infection another pathway, such as
affecting the p53 expression, is needed to drive the
malignant progression [4, 5].
The tumor suppressor gene TP53 has an important role
in inducing growth arrest and apoptosis and a dysregulation
of this gene is therefore highly beneficial for cancer
development [16]. In a normal cell, the protein mouse
double minute 2 (MDM2) can act as an E3 ubiquitin ligase
that can transfer ubiquitin to p53 which targets it to pro-
teasome-mediated degradation. In case of an high-risk
HPV infection, E6 binds to p53 and E6-associated protein
ligase (E6AP) forming a complex that ubiquitinates p53
and causes its degradation [6]. TP53 has been extensively
studied, and its variants, polymorphisms and mutations
have been amassed in several databases. From this infor-
mation, it is clear that p53 functionality is sensitive to a
wide range of singe nucleotide alterations. Whibley et al.
[17] raised the question as to whether some of the poly-
morphisms existing in a healthy population might also be
of importance for p53 function under certain circum-
stances. The polymorphism in codon 72 of TP53 is the
exchange from CCC, which encodes proline (pro), to CGC,
which encodes for arginine (arg). Codon 72 is located in
the proline-rich domain spanning from codon 64–92 [17].
The prevalence of the two alleles has been linked to a
selective difference related to winter temperature with
proline being more common in a warmer climate [18]. The
frequency of the polymorphic alleles in Sweden is reported
to be 9% for pro, 44% for heterozygous (arg/pro) and 47%
for arg [19]. Individuals carrying the arg allele have been
proposed to be more susceptible to cancer caused by HPV
[20]. This has led to further analyses showing that the
p53arg and p53pro differ in structure and these structural
differences are most likely located in the N-terminal por-
tion of the protein [21].
The polymorphism has been studied in relation to a wide
range of cancers with inconclusive results [17]. For cervi-
cal cancer, the interest has been relatively extensive due to
its strong relation with HPV infection [22, 23], while
studies on vaginal and vulvar cancer have been sparse [24].
The main focus in the majority of the studies has been the
importance of codon 72 on susceptibility to HPV-induced
cancer with only some addressing the prognostic value
[25]. Previous studies indicate that this common p53
polymorphism could affect tumor development and
response to treatment. Therefore, we wished to determine
the effect on prognosis and recurrence in vaginal and
vulvar carcinomas of p53 codon 72 polymorphisms, which




One hundred and thirty-three samples from patients with
vulvar squamous cell carcinoma (VSCC) and 78 samples
from patients with primary vaginal carcinoma were
obtained from the Biobank at the O¨rebro University
Hospital. The VSCC samples were originally collected
from O¨rebro University Hospital, Umea˚ University
Hospital, Uppsala University Hospital, and Central
Hospitals in Eskilstuna, Falun, Ga¨vle, Karlstad and Va¨s-
tera˚s (1983–2008). The vaginal carcinomas were originally
collected from O¨rebro University Hospital, and from
Central Hospitals in Eskilstuna, Karlstad and Va¨stera˚s
(1975–2002).
HPV genotyping and HPV-16 classification have been
performed on both cohorts by the research team in an
earlier phase [10, 11]. In these studies, three samples in the
vulvar cohort with questionable HPV status were excluded
and in the vaginal cohort four patients were excluded due
to insufficient tumor material, four due to difficulty
retrieving tumor material and one due to poor DNA qual-
ity. The samples above were excluded from this study
along with seven samples in the vulvar cohort and three
samples in the vaginal cohort that were excluded due to
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insufficient DNA material. In total, 123 cases in the vulvar
cohort and 66 cases in the vaginal cohort were analyzed.
All material was retrieved from formalin-fixed and
paraffin-embedded (FFPE) samples and tumors were
staged at the time of diagnosis according to FIGO guide-
lines [26]. Histological classification was performed
according to the nomenclature proposed by the World
Health Organization (WHO) [27]. Clinical data were
retrieved from patient records at the Department of
Gynecological Oncology, O¨rebro University Hospital. The
study was approved by the regional ethics committee board
in Uppsala (Dnr 2008/294), and informed consent was
given as specified in the ethical approval.
DNA extraction
Tumor areas were marked on hematoxylin–eosin-stained
sections and were punched out using a one-time disposable
1-mm skin biopsy punch (Miltex, GmbH, Germany). Tis-
sues were deparaffinized by routine procedure, and DNA
was extracted using QIAmp DNA Mini Kit (Qiagen,
GmbH, Hilden, Germany) according to instructions by the
manufacturer. DNA concentration was measured spec-
trophotometrically using a nanodrop (ND-1000, Saveen
and Werner, Limhamn, Sweden).
Real-time PCR
Samples were analyzed in 10 ll reactions with real-time
PCR containing a standardized Taqman Genotyping Master
Mix kit (Applied Biosystems, Foster city, CA, USA)
together with 1 9 Taqman SNP genotyping assays (assay
ID: C_2403545_10, Applied Biosystems) and 1.8 ng/ll
DNA. Initial denaturation was performed at 95 Cfor
10 min followed by 40 cycles of 95 C for 15 s and 60 C
for 1 min. Post-PCR allelic discrimination read was per-
formed in 60 C for 1 min with fluorescent markers VIC
and FAM illustrating the presence of the arginine and
proline allele, respectively. All runs contained a positive
control for each of the three possible outcomes (arg/arg,
arg/pro or pro/pro) as well as a negative control. Results
were analyzed using software 7500 Fast System SDS
Software (Applied Biosystems). All samples were analyzed
in triplicates and in case of non-evaluable results samples
were reanalyzed with the same conditions before per-
forming a re-extraction of DNA from the tumor material.
Statistical analysis
Survival curves were analyzed using the Kaplan–Meier
method, and differences were evaluated with the log-rank
test. Independent t test was used for comparing means and
for comparison of proportions the Pearson’s Chi-square test
was used. p values less than 0.05 were considered statis-
tically significant. Analyses were performed using the
Statistica software package (version 13, StatSoft, Inc.,
Tulsa, USA).
Results
Patient data and polymorphism
Sixty-six samples from the vaginal cohort and 123 samples
from the vulvar cohort were analyzed by targeting the
polymorphic variants, arginine and proline, of codon 72 in
p53. In the vaginal cohort 53.0% (35 cases) were arg/arg,
37.9% (25 cases) were arg/pro, and 4.5% (3 cases) were
pro/pro. In the vulvar cohort, 55.3% (68 cases) were arg/
arg, 35.8% (44 cases) were arg/pro, and 4.1% (5 cases)
were pro/pro (Table 1). Three samples (4.5%) from the
vaginal cohort and 6 samples (4.9%) from the vulvar cohort
were not classifiable and were placed in separate groups
marked as ‘‘undefined.’’
The mean age of patients in the vaginal cohort with arg/
arg tumors was 70.1 years (SD 12.4 years), for arg/pro
genotype tumors 68.5 years (SD 11.9 years), and for pro/
pro genotype tumors 65.7 years (SD 18.1 years). These
differences were not significant. In vulvar carcinoma, the
mean age at diagnosis of patients with arg/arg genotype
tumors was 69.7 years (SD 14.5 years), for pro/arg tumors
73.8 years (SD 12.0 years), and for pro/pro genotype
tumors 68.8 years (SD 11.0 years). No significant differ-
ences were found.
HPV association and tumor characteristics
The vaginal cohort consisted of 35 HPV-positive cases and
31 HPV-negative cases. The arg/arg polymorphism
(57.1%) was more common than the arg/pro variant
(40.0%) in HPV-positive tumors, and the opposite was seen
in HPV-negative tumors (42.9 vs. 60.0%). The difference
was not statistically significant (Pearson v2; p = 0.190)
(Table 2).
Table 1 Prevalence of the polymorphic variants of the p53 codon 72
in vaginal and vulvar carcinomas
TP53 allele Vaginal cohort Vulvar cohort
No. 66 % 123 %
arg/arg 35 53.0 68 55.3
arg/pro 25 37.9 44 35.8
pro/pro 3 4.5 5 4.1
undefined 3 4.5 6 4.9
arg arginine, pro proline
Med Oncol  (2017) 34:36 Page 3 of 8  36 
123
The vulvar cohort consisted of 38 HPV-positive cases
and 85 HPV-negative cases. The various types of poly-
morphism were similarly distributed in HPV-positive and
HPV-negative cases (Pearson v2; p = 0.771) (Table 2). A
majority of the HPV-positive cases were positive for HPV-
16 (71.4% in the vaginal cohort and 78.9% in the vulvar
cohort), and the other cases were spread on different HPV
types (data not shown). To achieve a reasonable number of
cases in the compared groups, the HPV-16-positive cases
were separated from the other types which were combined
into one group. No difference in allele distributions was
seen in the two constructed groups in either cohort. HPV-
16 variant data were too sparse for meaningful statistical
analyses in this study.
Tumor stage was not significantly associated with codon
72 polymorphism in the vaginal cohort (Table 2). In the
vulvar cohort, tumors in advanced stages (III–IV) had arg/
arg genotype in 25/36 (69.4%) of the cases and tumors in
early stages (I–II) in 43/81 (53.1%) of evaluable cases
(Pearson v2; p = 0.098) (Table 2).
Tumor size at diagnosis in the vaginal cohort was
similar for tumors with arg/arg and arg/pro genotype (mean
diameter 24.0 vs. 24.4 mm; t test, p = 0.896). Tumor
localization in the vagina was not associated with the
present genotype at codon 72 (arg/arg vs. arg/pro). How-
ever, tumors with an arg/arg genotype at codon 72 were
significantly (t test; p = 0.015) larger at diagnosis (mean
diameter 36 mm, SD 23 mm) than tumors with arg/pro or
pro/pro genotypes (mean 25 mm, SD 14 mm) in the vulvar
cohort. Data on tumor size at diagnosis were only evalu-
able on 84 out of 130 cases (64.6%).
Type of histology was not significantly associated with
polymorphism in the vaginal cohort (Table 2). In the vul-
var cohort, arg/arg genotype was more frequent (73.7%) in
tumors of mixed type than in tumors of basaloid or kera-
tinizing type (55.1%), however, not significant (Pearson v2;
p = 0.133) (Table 2).
Clinical outcome
Primary cure rate
Vaginal carcinomas The primary cure rate of the com-
plete series was 53 out of 66 (80.3%) cases. Among tumors
achieving primary cure (complete remission) in the vaginal
group, the arg/arg genotype was significantly (Pearson v2;
p = 0.023) more common (66.0%) than in tumors not
achieving primary cure (30.8%).
Vulvar carcinomas The primary cure rate of the complete
series was 116 out of 123 (88.6%) cases. The primary cure
was 91.2% in the arg/arg group and 86.4% in the arg/pro
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Tumor recurrences
Vaginal carcinomas Arg/arg genotype was more com-
mon (15/21, 71.4%) in tumors with recurrences (all types
and sites) than in tumors with no recurrences (20/42,
47.6%) (Pearson v2; p = 0.073). In tumors with distant
recurrences, this difference was more pronounced (10/11,
90.9% vs. 25/52, 48.1%) and highly statistically significant
(Pearson v2; p = 0.009).
Vulvar carcinomas In the vulvar cohort, the overall
recurrence rate was 31/68 (45.6%) among tumors with arg/
arg genotype and 17/49 (34.7%) in tumors with arg/pro or
pro/pro genotype (Pearson v2; p = 0.237). Local vulvar
recurrences were similar in tumors with arg/arg genotype
(16/68, 23.5%) and in tumors with arg/pro or pro/pro
genotype (12/49, 24.5%) (Pearson v2; p = 0.904). Inguinal
lymph node recurrences were recorded in 11/68 (16.2%)
tumors with arg/arg genotype and in 6/49 (12.2%) tumors
with arg/pro or pro/pro genotype (Pearson v2; p = 0.552).
Distant recurrences were recorded in 4/68 (5.9%) tumors
with arg/arg genotype and in 4/49 (8.2%) tumors with pro/
arg or pro/pro genotype (Pearson v2; p = 0.630).
Survival rate
Vaginal carcinomas In the vaginal cohort, the arg/arg
genotype was associated with a numerically, but not sig-
nificantly (log-rank test; p = 0.609) worse 5-year cancer-
specific survival (CSS) rate (43.6%) than the pro/arg
genotype (53.4%). Neither overall survival rate was sig-
nificantly (log-rank test; p = 0.554) different for the ana-
lyzed genotype groups. Patients with HPV-positive tumors
and arg/arg genotype had a similar 5-year CSS (72.2%) to
patients with the arg/pro genotype (80.0%) (log-rank test;
p = 0.821). In patients with HPV-negative tumors, the
rates were 53.8% for arg/arg and 43.4% for arg/pro patients
(log-rank test; p = 0.607).
Vulvar carcinomas The 5-year overall survival rate in the
vulvar cohort was 40.1% for patients with tumors showing
the arg/arg genotype and 67.4% for patients with tumors
showing the pro/arg genotype (log-rank test; p = 0.065).
The corresponding CSS rates were 51.5 and 72.7%,
respectively (log-rank test; p = 0.169). When the pro/pro
genotype group was combined with undefined cases and
compared with the other two groups, the survival rate was
very similar to the pro/arg group (73.8% 5-year cancer-
specific survival rate). In the vulvar cohort, patients with
HPV-positive tumors had similar CSS survival rates for the
genotypes arg/arg and arg/pro (69.8 vs. 73.5%; log-rank
test; p = 0.283). However, different CSS survival rates
were observed for arg/arg and arg/pro polymorphism in
HPV-negative patients (43.9 vs. 72.2%; log-rank test;
p = 0.024).
Discussion
In this study, we have evaluated the importance of the
codon 72 polymorphism in p53 on clinical outcome in
cancer of the vagina and vulva as well as its association
with HPV status, obtained from previous studies. We found
that the significance of the polymorphism differed between
the two cohorts. Despite a higher primary cure rate for
tumors with the arg/arg genotype, distant recurrences were
significantly more common among patients where tumors
had the arg/arg genotype compared with the arg/pro
genotype in the vaginal carcinoma group. For patients with
the arg/arg genotype, in the vulvar carcinomas, tumors
were significantly larger at diagnosis compared to the arg/
pro genotype. In both cohorts, the arg/arg genotype
numerically indicated a worse cancer-specific survival, but
a statistically significant association was found in the vul-
var HPV-negative group only.
Codon 72 polymorphism of p53 did not have a signifi-
cant association with HPV status in our study. A non-
significant higher frequency of arginine homozygotes
compared to heterozygotes was noted in the HPV-positive
vaginal carcinoma patients. To further elude potential
impact of p53 polymorphism in relation to HPV status,
survival rate was analyzed in both patient groups. Inter-
estingly, for patients with vulvar carcinoma, positive for
HPV, the allelic variant arg/arg had no impact on survival.
Potentially, HPV is the major prognostic factor for these
patients, and not the investigated polymorphism. On the
other hand, for patients with HPV-negative vulvar tumors
and the arg/arg polymorphism, we show a significantly
worse cancer-specific survival rate. Despite the significant
finding in univariate analysis, increased tumor size in arg/
arg patients was not an independent factor in multivariate
analysis (data not shown) and has therefore probably not
affected the survival outcome. Few studies have addressed
the prognostic value of this polymorphism with studies
focusing on HPV-negative cases being almost absent.
However, a worse overall survival and lower progression-
free survival have been observed in a cohort of nasopha-
ryngeal carcinoma with the arg/arg genotype [28].
To further analyze an association between the codon 72
polymorphism and HPV, different HPV genotypes were
compared, with no significant differences. Duin et al. [29]
performed a study on cervical carcinoma patients that
showed increased risk for developing cancer for women
homozygous for arginine with the 350T variant of HPV-16.
Unfortunately, our earlier performed HPV-16 sub-geno-
typing yielded too small groups to identify any association
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and therefore no statistical analysis could be performed to
verify or challenge the previous results. The impact of HPV
and p53 codon 72 polymorphism on patient prognosis
remains an intriguing subject for further studies.
We previously showed that the tumors expressing mixed
histology in vulvar squamous cell carcinomas had a sig-
nificant worse survival than the other histological types and
was associated with an unfavorable tumor stage distribu-
tion with less stage I and more stage IV tumors than the
other histological types [11]. In the present study, we
showed an association of arginine homozygosity with the
mixed type of histology, higher tumor stage, a significantly
larger tumor size at diagnosis and a numerically worse
survival outcome. A higher tumor stage and larger size at
diagnosis have earlier been shown to be significant prog-
nostic markers for survival [8–11, 14], and the examined
polymorphism may be an additional factor in combination
with these clinical tumor parameters.
Sullivan et al. [25] showed that patients with head and
neck cancer carrying the arginine allele had a better response
to chemo-radiotherapy than patients with other alleles. This
is in agreement with our results in the vaginal cohort where
higher primary cure rate was seen in arginine homozygotes.
Further support for this result is the in vitro studies investi-
gating the impact of the polymorphism of codon 72 on p53
function finding that the p53arg induces apoptosis to a
greater extent and with a faster kinetics than p53pro
[21, 25, 30, 31]. When exposed to stress, p53arg is trans-
ported out of the nucleus and localizes to the mitochondria,
while p53pro to a higher extent remains in the nucleus
[30, 32, 33]. Deletion of the proline-rich region has been
shown to strongly impede the apoptotic function of the p53
protein [34], resulting in a stronger affinity of p53 to MDM2
with higher susceptibility to ubiquitination almost solely
occurring in the nucleus [35]. The mitochondrial localization
gives a position advantage for p53arg to interact with pro-
apoptotic proteins residing at the mitochondrial surface,
while the nucleus-located p53pro might experience higher
MDM2 degradation [30, 32, 33].
In contrast to Sullivan et al., our superior primary cure
rate in vaginal cancer patients, homozygous for arginine,
was not associated with increased survival and these
patients also had a higher recurrence rate. In comparison
with the cohort used by Sullivan et al., where all patients
were treated with chemo-radiotherapy, almost all vaginal
cancer patients in the current study were treated with
radiation alone. Also, 72% of the vulvar cancer patients
were treated with primary surgery and adjuvant radiother-
apy. Statistical analysis showed that the different treat-
ments did not affect either recurrence rate or survival
outcome in the vaginal carcinoma patients (data not
shown). An interesting result in our study was the pro-
nounced significance of the arginine genotype in the distant
recurrences of vaginal carcinomas. This leads to the
assumption that the arginine homozygous tumor cells may
have a biological advantage for spreading compared with
the other groups. Different expression levels between the
polymorphic variants as an explanation are unlikely since
metastases have been shown to have lower p53 expression
than their primary tumor [36] and levels between the
arginine and proline variant have been shown to be equal
[21, 30]. A more plausible explanation is the observed
difference in protein interactions between arginine and
proline. Differences in interactions inducing transcriptional
activity of certain apoptotic target genes have been
observed, with the p53arg being more potent [31, 33]. On
the contrary, p53pro has a higher affinity to p53 inhibitors
and is more susceptible to MDM2-mediated degradation,
but is also more efficient at inducing cell cycle arrest and
DNA repair than p53arg [21, 25, 30].
The most recognized function of p53 is the induction of
apoptosis, but it also plays a role in a wide variety of
cellular processes, of which many are yet to be fully
understood [37]. It has been shown that p53 is more
effective at inducing a wider variety of proteins when
present at several locations [38]. Since the intracellular
locations and structures of arginine and proline variants
have been shown to differ, their protein interactions and
affinity might also vary.
p53 has also been implicated in the control of other
proteins involved in cell motility and invasiveness [39, 40].
p53 can affect cell motility through affecting the PI3-ki-
nase/Rac1 pathway in the presence of mitogenic factors in
both normal cells and tumor cells [41] and forms a complex
with MDM2 and an invasion promotor named SLUG, an
E-cadherin transcription inhibitor, leading to degradation
of the complex [42]. As previously mentioned, p53
homozygous for arginine at codon 72 appears to be resis-
tant to MDM2-mediated degradation compared to the
proline variant. If this resistance is due to alterations in the
binding of MDM2 to p53, then the same scenario might be
present in the complex containing SLUG.
A possible explanation for diverging results between the
vaginal and vulvar tumor types might be a tissue-specific
response in the vagina and vulva, reflecting the use of
different pathways of apoptosis in different tissues
although both being squamous cell carcinomas. The effect
on apoptosis, visualized in mouse models, has shown that
p53arg is superior in skin and intestine, p53pro more
prominent in the thymus and with no difference in the
spleen [33, 43]. p53 has also shown various induction of
proteins in different tissues [44], indicating that a tissue-
specific predisposition for several pathways used by p53
might be present.
Some limitations of our study are worth to acknowledge.
Due to the rareness of the investigated cancers, the cohorts
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used are small and the inflated false positive or negative
rates needs to be considered. When using formalin-fixed
and paraffin-embedded tissue, there is also a risk of DNA
fragmentation [45]. The unclassifiable results might be
caused by loss of p53 wildtype or loss of heterozygosity.
Reports have shown a preferential retention of the arginine
allele compared to the proline allele [46]. The prevalence
of these potential limitations was not further evaluated in
this study.
In conclusion, we report different results between
vaginal and vulvar carcinomas regarding the p53 codon 72
polymorphism. For vaginal cancer, recurrence rate is
affected while survival is left unperturbed in the complete
series, and also in HPV-positive and HPV-negative cases
when analyzed separately. On the contrary, the survival
outcome is affected in HPV-negative vulvar cancer, but not
in HPV-positive cases. Larger tumor size was also seen in
arginine homozygous patients. This study is to our
knowledge the first investigating this relationship, and
more comprehensive studies are needed to further analyze
the importance of p53 codon 72 polymorphism as a clinical
prognostic factor in established carcinomas of the vagina
and vulva.
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